News-Medical - Mount Sinai Scientists Receive NIH Grant to Study Clinical Benefit of IGF-1 in Children with PMS
Scientists at the Seaver Autism Center at the Icahn School of Medicine at Mount Sinai have received a grant from the National Institutes of Health (NIH) to study Insulin-Like Growth Factor-1 (IGF-1), a promising treatment for a subtype of autism called Phelan McDermid Syndrome (PMS). The grant will allow researchers to expand upon an ongoing study assessing the clinical benefit of IGF-1 in children with this severe type of autism. With the grant, Alex Kolevzon, MD, Clinical Director the Seaver Autism Center and Associate Professor of Psychiatry and Pediatrics at the Icahn School of Medicine at Mount Sinai, will continue to enroll children ages 5 to 12 years old who have PMS in this double-blind, placebo-controlled crossover study.
-Dr. Alexander Kolevzon, Clinical Director, Seaver Autism Center, Associate Professor, Psychiatry, Pediatrics, Icahn School of Medicine at Mount Sinai